Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy
We sought to investigate whether serum immune and inflammatory parameters can help to predict distant metastasis (DM) in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT). A total of 76 RT courses were analyzed. The following variables were included...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-03, Vol.15 (7), p.1978 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 1978 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Lee, Dong Soo Kim, Chang Wook Kim, Hee Yeon Ku, Young-Mi Won, Yoo Dong Lee, Su-Lim Sun, Der Sheng |
| description | We sought to investigate whether serum immune and inflammatory parameters can help to predict distant metastasis (DM) in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT).
A total of 76 RT courses were analyzed. The following variables were included in the analysis: systemic inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), absolute lymphocyte count, lymphocyte-to-monocyte ratio, albumin, albumin-to-alkaline phosphatase ratio, RT-related parameters, and levels of total protein, hemoglobin, α-fetoprotein, and PIVKA-II. Distant control (DC) and overall survival (OS) rates were calculated and compared.
The mean age was 61.4 years, and most patients were men (
= 62, 81.6%). The median RT fraction number and fractional doses were 12 (range, 4-30) and 5 (range, 2-12) Gy, respectively. With a median follow-up of 12 (range, 3.1-56.7) months, the 1-year DC and OS rates were 64.4% and 55.2%, respectively. The development of DM significantly deteriorated OS (
= 0.013). In the multivariate analysis, significant independent prognostic indicators for DC and OS rates were the highest posttreatment PLR (≤235.7 vs. >235.7,
= 0.006) and the lowest posttreatment PNI (≤25.4 vs. >25.4,
< 0.001), respectively.
Posttreatment serum PLR might be helpfully used as a predictive biomarker of DM in unresectable HCC patients undergoing RT. Future research is necessary to confirm our findings. |
| doi_str_mv | 10.3390/cancers15071978 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10092989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A746926070</galeid><sourcerecordid>A746926070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-3f0d56f88151e907312de5dcf959554aec8ec59067309be12469959aa52ab9883</originalsourceid><addsrcrecordid>eNptUsFu1DAQjRCIVqVnbsgSFy5p7TiO4xNabYEiLaIq5WzNOpNdV4m92M5W-0t8JV51KW2FLXlGnvee31hTFG8ZPeNc0XMDzmCITFDJlGxfFMcVlVXZNKp--Sg_Kk5jvKV5cc5kI18XR1zSumm4Oi5-z2L0xkKy3pElpjtER658TCkgpBFdIj8wTCO5GiDhgKlMvlzsxs3am11Ccr1nEnAdubAxQYZ_wwQ5ixiJzVK5nkUiubNpTS5xA8kbHIZpgEDmEIx1fgRyjQbt1roVmU8hU7Z75e5g62aNATa7N8WrHoaIp4d4Uvz8_Olmflkuvn_5Op8tSlPXPJW8p51o-rZlgqGikrOqQ9GZXgklRA1oWjRC0UZyqpbIqrpRuQQgKliqtuUnxcd73c20HLEz2X6AQW-CHSHstAern1acXeuV32pGqapUq7LCh4NC8L8mjEmPNu67Bod-irpqKW3yIViGvn8GvfVTcLk_XcnsSzSStv9QKxhQW9f7_LDZi-qZzP6rhkqaUWf_QeXd4WiNd9jbfP-EcH5PMMHHGLB_aJJRvR8x_WzEMuPd4795wP8dKP4H75zQug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799556708</pqid></control><display><type>article</type><title>Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lee, Dong Soo ; Kim, Chang Wook ; Kim, Hee Yeon ; Ku, Young-Mi ; Won, Yoo Dong ; Lee, Su-Lim ; Sun, Der Sheng</creator><creatorcontrib>Lee, Dong Soo ; Kim, Chang Wook ; Kim, Hee Yeon ; Ku, Young-Mi ; Won, Yoo Dong ; Lee, Su-Lim ; Sun, Der Sheng</creatorcontrib><description>We sought to investigate whether serum immune and inflammatory parameters can help to predict distant metastasis (DM) in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT).
A total of 76 RT courses were analyzed. The following variables were included in the analysis: systemic inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), absolute lymphocyte count, lymphocyte-to-monocyte ratio, albumin, albumin-to-alkaline phosphatase ratio, RT-related parameters, and levels of total protein, hemoglobin, α-fetoprotein, and PIVKA-II. Distant control (DC) and overall survival (OS) rates were calculated and compared.
The mean age was 61.4 years, and most patients were men (
= 62, 81.6%). The median RT fraction number and fractional doses were 12 (range, 4-30) and 5 (range, 2-12) Gy, respectively. With a median follow-up of 12 (range, 3.1-56.7) months, the 1-year DC and OS rates were 64.4% and 55.2%, respectively. The development of DM significantly deteriorated OS (
= 0.013). In the multivariate analysis, significant independent prognostic indicators for DC and OS rates were the highest posttreatment PLR (≤235.7 vs. >235.7,
= 0.006) and the lowest posttreatment PNI (≤25.4 vs. >25.4,
< 0.001), respectively.
Posttreatment serum PLR might be helpfully used as a predictive biomarker of DM in unresectable HCC patients undergoing RT. Future research is necessary to confirm our findings.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15071978</identifier><identifier>PMID: 37046639</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Albumin ; Alkaline phosphatase ; Biomarkers ; Blood platelets ; Cancer therapies ; Cardiovascular disease ; Care and treatment ; Cell number ; Complications and side effects ; Health aspects ; Hemoglobin ; Hepatocellular carcinoma ; Hepatoma ; Inflammation ; Leukocytes (neutrophilic) ; Liver cancer ; Lymphocytes ; Medical imaging ; Medical prognosis ; Metastases ; Metastasis ; Methods ; Monocytes ; Mortality ; Multivariate analysis ; Neutrophils ; Patient outcomes ; Patients ; Phosphatase ; Planning ; Platelets ; Population ; Quality of life ; Radiation therapy ; Radiotherapy ; Risk factors ; Survival analysis ; α-Fetoprotein</subject><ispartof>Cancers, 2023-03, Vol.15 (7), p.1978</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-3f0d56f88151e907312de5dcf959554aec8ec59067309be12469959aa52ab9883</cites><orcidid>0000-0003-1184-0358 ; 0000-0003-0677-2098 ; 0000-0001-7880-8147</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092989/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092989/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37046639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Dong Soo</creatorcontrib><creatorcontrib>Kim, Chang Wook</creatorcontrib><creatorcontrib>Kim, Hee Yeon</creatorcontrib><creatorcontrib>Ku, Young-Mi</creatorcontrib><creatorcontrib>Won, Yoo Dong</creatorcontrib><creatorcontrib>Lee, Su-Lim</creatorcontrib><creatorcontrib>Sun, Der Sheng</creatorcontrib><title>Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>We sought to investigate whether serum immune and inflammatory parameters can help to predict distant metastasis (DM) in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT).
A total of 76 RT courses were analyzed. The following variables were included in the analysis: systemic inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), absolute lymphocyte count, lymphocyte-to-monocyte ratio, albumin, albumin-to-alkaline phosphatase ratio, RT-related parameters, and levels of total protein, hemoglobin, α-fetoprotein, and PIVKA-II. Distant control (DC) and overall survival (OS) rates were calculated and compared.
The mean age was 61.4 years, and most patients were men (
= 62, 81.6%). The median RT fraction number and fractional doses were 12 (range, 4-30) and 5 (range, 2-12) Gy, respectively. With a median follow-up of 12 (range, 3.1-56.7) months, the 1-year DC and OS rates were 64.4% and 55.2%, respectively. The development of DM significantly deteriorated OS (
= 0.013). In the multivariate analysis, significant independent prognostic indicators for DC and OS rates were the highest posttreatment PLR (≤235.7 vs. >235.7,
= 0.006) and the lowest posttreatment PNI (≤25.4 vs. >25.4,
< 0.001), respectively.
Posttreatment serum PLR might be helpfully used as a predictive biomarker of DM in unresectable HCC patients undergoing RT. Future research is necessary to confirm our findings.</description><subject>Albumin</subject><subject>Alkaline phosphatase</subject><subject>Biomarkers</subject><subject>Blood platelets</subject><subject>Cancer therapies</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Cell number</subject><subject>Complications and side effects</subject><subject>Health aspects</subject><subject>Hemoglobin</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Inflammation</subject><subject>Leukocytes (neutrophilic)</subject><subject>Liver cancer</subject><subject>Lymphocytes</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Monocytes</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Neutrophils</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Phosphatase</subject><subject>Planning</subject><subject>Platelets</subject><subject>Population</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Risk factors</subject><subject>Survival analysis</subject><subject>α-Fetoprotein</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUsFu1DAQjRCIVqVnbsgSFy5p7TiO4xNabYEiLaIq5WzNOpNdV4m92M5W-0t8JV51KW2FLXlGnvee31hTFG8ZPeNc0XMDzmCITFDJlGxfFMcVlVXZNKp--Sg_Kk5jvKV5cc5kI18XR1zSumm4Oi5-z2L0xkKy3pElpjtER658TCkgpBFdIj8wTCO5GiDhgKlMvlzsxs3am11Ccr1nEnAdubAxQYZ_wwQ5ixiJzVK5nkUiubNpTS5xA8kbHIZpgEDmEIx1fgRyjQbt1roVmU8hU7Z75e5g62aNATa7N8WrHoaIp4d4Uvz8_Olmflkuvn_5Op8tSlPXPJW8p51o-rZlgqGikrOqQ9GZXgklRA1oWjRC0UZyqpbIqrpRuQQgKliqtuUnxcd73c20HLEz2X6AQW-CHSHstAern1acXeuV32pGqapUq7LCh4NC8L8mjEmPNu67Bod-irpqKW3yIViGvn8GvfVTcLk_XcnsSzSStv9QKxhQW9f7_LDZi-qZzP6rhkqaUWf_QeXd4WiNd9jbfP-EcH5PMMHHGLB_aJJRvR8x_WzEMuPd4795wP8dKP4H75zQug</recordid><startdate>20230326</startdate><enddate>20230326</enddate><creator>Lee, Dong Soo</creator><creator>Kim, Chang Wook</creator><creator>Kim, Hee Yeon</creator><creator>Ku, Young-Mi</creator><creator>Won, Yoo Dong</creator><creator>Lee, Su-Lim</creator><creator>Sun, Der Sheng</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1184-0358</orcidid><orcidid>https://orcid.org/0000-0003-0677-2098</orcidid><orcidid>https://orcid.org/0000-0001-7880-8147</orcidid></search><sort><creationdate>20230326</creationdate><title>Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy</title><author>Lee, Dong Soo ; Kim, Chang Wook ; Kim, Hee Yeon ; Ku, Young-Mi ; Won, Yoo Dong ; Lee, Su-Lim ; Sun, Der Sheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-3f0d56f88151e907312de5dcf959554aec8ec59067309be12469959aa52ab9883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Albumin</topic><topic>Alkaline phosphatase</topic><topic>Biomarkers</topic><topic>Blood platelets</topic><topic>Cancer therapies</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Cell number</topic><topic>Complications and side effects</topic><topic>Health aspects</topic><topic>Hemoglobin</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Inflammation</topic><topic>Leukocytes (neutrophilic)</topic><topic>Liver cancer</topic><topic>Lymphocytes</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Monocytes</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Neutrophils</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Phosphatase</topic><topic>Planning</topic><topic>Platelets</topic><topic>Population</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Risk factors</topic><topic>Survival analysis</topic><topic>α-Fetoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Dong Soo</creatorcontrib><creatorcontrib>Kim, Chang Wook</creatorcontrib><creatorcontrib>Kim, Hee Yeon</creatorcontrib><creatorcontrib>Ku, Young-Mi</creatorcontrib><creatorcontrib>Won, Yoo Dong</creatorcontrib><creatorcontrib>Lee, Su-Lim</creatorcontrib><creatorcontrib>Sun, Der Sheng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Dong Soo</au><au>Kim, Chang Wook</au><au>Kim, Hee Yeon</au><au>Ku, Young-Mi</au><au>Won, Yoo Dong</au><au>Lee, Su-Lim</au><au>Sun, Der Sheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-03-26</date><risdate>2023</risdate><volume>15</volume><issue>7</issue><spage>1978</spage><pages>1978-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>We sought to investigate whether serum immune and inflammatory parameters can help to predict distant metastasis (DM) in patients with unresectable hepatocellular carcinoma (HCC) undergoing curative radiation therapy (RT).
A total of 76 RT courses were analyzed. The following variables were included in the analysis: systemic inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), absolute lymphocyte count, lymphocyte-to-monocyte ratio, albumin, albumin-to-alkaline phosphatase ratio, RT-related parameters, and levels of total protein, hemoglobin, α-fetoprotein, and PIVKA-II. Distant control (DC) and overall survival (OS) rates were calculated and compared.
The mean age was 61.4 years, and most patients were men (
= 62, 81.6%). The median RT fraction number and fractional doses were 12 (range, 4-30) and 5 (range, 2-12) Gy, respectively. With a median follow-up of 12 (range, 3.1-56.7) months, the 1-year DC and OS rates were 64.4% and 55.2%, respectively. The development of DM significantly deteriorated OS (
= 0.013). In the multivariate analysis, significant independent prognostic indicators for DC and OS rates were the highest posttreatment PLR (≤235.7 vs. >235.7,
= 0.006) and the lowest posttreatment PNI (≤25.4 vs. >25.4,
< 0.001), respectively.
Posttreatment serum PLR might be helpfully used as a predictive biomarker of DM in unresectable HCC patients undergoing RT. Future research is necessary to confirm our findings.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37046639</pmid><doi>10.3390/cancers15071978</doi><orcidid>https://orcid.org/0000-0003-1184-0358</orcidid><orcidid>https://orcid.org/0000-0003-0677-2098</orcidid><orcidid>https://orcid.org/0000-0001-7880-8147</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-03, Vol.15 (7), p.1978 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10092989 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Albumin Alkaline phosphatase Biomarkers Blood platelets Cancer therapies Cardiovascular disease Care and treatment Cell number Complications and side effects Health aspects Hemoglobin Hepatocellular carcinoma Hepatoma Inflammation Leukocytes (neutrophilic) Liver cancer Lymphocytes Medical imaging Medical prognosis Metastases Metastasis Methods Monocytes Mortality Multivariate analysis Neutrophils Patient outcomes Patients Phosphatase Planning Platelets Population Quality of life Radiation therapy Radiotherapy Risk factors Survival analysis α-Fetoprotein |
| title | Association between Posttreatment Serum Platelet-to-Lymphocyte Ratio and Distant Metastases in Patients with Hepatocellular Carcinoma Receiving Curative Radiation Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A37%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20Posttreatment%20Serum%20Platelet-to-Lymphocyte%20Ratio%20and%20Distant%20Metastases%20in%20Patients%20with%20Hepatocellular%20Carcinoma%20Receiving%20Curative%20Radiation%20Therapy&rft.jtitle=Cancers&rft.au=Lee,%20Dong%20Soo&rft.date=2023-03-26&rft.volume=15&rft.issue=7&rft.spage=1978&rft.pages=1978-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15071978&rft_dat=%3Cgale_pubme%3EA746926070%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2799556708&rft_id=info:pmid/37046639&rft_galeid=A746926070&rfr_iscdi=true |